Cyclin-dependent kinase 4/6 inhibitors

Overview

Cyclin-dependent kinase 4/6 inhibitors are a class of targeted anticancer therapies that block the activity of Cdk4 and CDK6, key regulators of cell-cycle progression from the G1 phase to the S phase. By inhibiting these kinases, the drugs reduce phosphorylation of retinoblastoma pathway components and slow proliferation of tumor cells that depend on cyclin D–Cdk4/6 signaling. In clinical oncology, this mechanism has made Cdk4/6 inhibitors an important component of endocrine-based treatment strategies, especially in hormone receptor-positive, HER2-negative advanced breast cancer.

The best-established clinical role of this drug class is in combination with hormone therapy, where Cdk4/6 inhibitors are used to enhance and prolong disease control. Their use has also prompted investigation into broader biologic effects, including differences in toxicity profiles among agents such as palbociclib and abemaciclib, and potential interactions with immune and inflammatory pathways such as PD-L1, the cGAS-STING pathway, and systemic markers like C-reactive protein. Outside breast cancer, research has explored whether these agents may have activity in other malignancies, although benefits have been more limited in some settings.

Focus of Latest Publications

Recent publications consistently describe Cdk4/6 inhibitors as a central treatment option in hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. One review on first- and second-line management states that Cdk4/6 inhibitors are the preferred first-line therapy for most patients with HR+HER2-negative advanced breast cancer. A real-world sub-analysis in older patients similarly notes that endocrine therapy plus a Cdk4/6 inhibitor is the standard first-line treatment regardless of age, while examining whether effectiveness in older populations is maintained in routine practice.

Several studies focused on real-world outcomes in metastatic breast cancer. One analysis evaluated first-line Cdk4/6 inhibitor plus aromatase inhibitor therapy in US routine clinical practice, specifically assessing real-world progression-free survival 2 and tumor response. Another real-world study from India examined experience with palbociclib and ribociclib in HR+/HER2-negative metastatic breast cancer. Together, these reports reinforce the position of Cdk4/6 inhibitors as a standard backbone of endocrine-based therapy and highlight ongoing interest in how these agents perform outside randomized trials.

Safety and tolerability were also a major theme. A triangulation study comparing abemaciclib and palbociclib investigated divergent neuropsychiatric and systemic toxicity profiles, using pharmacovigilance and multi-omics approaches to suggest that clinically meaningful differences may exist between agents in this class. This is relevant because treatment selection in practice often depends not only on efficacy but also on adverse-event patterns, patient comorbidity, and tolerability alongside hormone therapy.

Beyond breast cancer, the class has been explored in other tumor types with less encouraging results. In esophageal squamous cell carcinoma, Cdk4/6 inhibitors such as palbociclib were described as having been tested only as second-line agents, often in combination with EGFR inhibitors, with minimal benefit. This suggests that the therapeutic value of Cdk4/6 inhibition is context dependent and may require tumor-specific biomarkers or combination strategies to achieve meaningful activity.

The related entities mentioned in these studies help frame the broader research landscape. nivolumab and PD-L1 reflect interest in immune checkpoint biology, while the cGAS-STING pathway and C-reactive protein point to inflammatory and immune-modulatory effects that may intersect with Cdk4/6 inhibitor exposure. anxiety was included among the toxicity-related outcomes in pharmacovigilance-oriented work, underscoring that these agents may have systemic and neuropsychiatric effects in addition to hematologic and gastrointestinal toxicities. Antibody-drug conjugates and hormone therapy represent other therapeutic classes relevant to treatment sequencing and combination strategies in advanced breast cancer.

Key Publications

• Jun Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. (The oncologist, 2026, PMID 42266036): "CDK4/6 inhibitors are the preferred first-line therapy for most patients."
• Jun Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice. (Breast (Edinburgh, Scotland), 2026, PMID 41950642): "This analysis compared rwPFS2 and rwTR in patients with HR+/HER2- mBC receiving first-line (1L) CDK4/6i plus an aromatase inhibitor (AI) in US routine clinical practice."
• Jun Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study. (Breast (Edinburgh, Scotland), 2026, PMID 42048902): "Endocrine therapy (ET) plus CDK4/6 inhibitors (CDK4/6i) is the standard first-line treatment regardless of age; however, CDK4/6i real-world effectiveness in older patients is unknown."
• May CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. (Cell death & disease, 2026, PMID 42215475): "CDK4/6 inhibitors such as palbociclib have only been tested as second-line agents in eSCC, often in combination with EGFR inhibitors, with minimal benefit."
• May Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India. (PloS one, 2026, PMID 42139194): "The present study evaluated the real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR + /HER2-) metastatic breast cancer."
• May Divergent neuropsychiatric and systemic toxicity profiles of abemaciclib and palbociclib: a triangulation study integrating pharmacovigilance, genetic epidemiology, and multi-omics profiling. (Naunyn-Schmiedeberg's archives of pharmacology, 2026, PMID 42091703): "Cyclin-dependent kinase 4/6 inhibitors improve outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, but their toxicity profiles may differ in clinically meaningful ways."